215 related articles for article (PubMed ID: 34439172)
1. Salvage Radioligand Therapy with Repeated Cycles of
Groener D; Baumgarten J; Haefele S; Happel C; Klimek K; Mader N; Nguyen Ngoc C; Tselis N; Chun FKH; Grünwald F; Sabet A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439172
[TBL] [Abstract][Full Text] [Related]
2. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of [
Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
[No Abstract] [Full Text] [Related]
4. Intermittent Radioligand Therapy with
Mader N; Schoeler C; Pezeshkpour N; Klimek K; Groener D; Happel C; Tselis N; Mandel P; Grünwald F; Sabet A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760574
[No Abstract] [Full Text] [Related]
5. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
6. Hematologic safety of
Groener D; Nguyen CT; Baumgarten J; Bockisch B; Davis K; Happel C; Mader N; Nguyen Ngoc C; Wichert J; Banek S; Mandel P; Chun FKH; Tselis N; Grünwald F; Sabet A
EJNMMI Res; 2021 Jul; 11(1):61. PubMed ID: 34216290
[TBL] [Abstract][Full Text] [Related]
7. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
9. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of
Baumgarten J; Groener D; Nguyen Ngoc C; Mader N; Chaurasia M; Davis K; Wichert J; Chun FKH; Tselis N; Happel C; Grünwald F; Sabet A
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158825
[TBL] [Abstract][Full Text] [Related]
11. Outcome of
Mader N; Groener D; Tselis N; Banek S; Nagarajah J; Grünwald F; Sabet A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439347
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C
PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962
[TBL] [Abstract][Full Text] [Related]
13. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of [
Rosar F; Krause J; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Ezziddin S; Khreish F
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34069003
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
16.
Bu T; Zhang L; Yu F; Yao X; Wu W; Zhang P; Shi L; Zang S; Meng Q; Ni Y; Shao G; Qiu X; Ai S; Jia R; Guo H; Wang F
Front Oncol; 2022; 12():835956. PubMed ID: 35402274
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of standardized
Rasul S; Hacker M; Kretschmer-Chott E; Leisser A; Grubmüller B; Kramer G; Shariat S; Wadsak W; Mitterhauser M; Hartenbach M; Haug AR
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):713-720. PubMed ID: 31781834
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow impairment during early [
Kind F; Michalski K; Yousefzadeh-Nowshahr E; Meyer PT; Mix M; Ruf J
EJNMMI Res; 2022 Apr; 12(1):20. PubMed ID: 35403915
[TBL] [Abstract][Full Text] [Related]
20. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [
Ahmadzadehfar H; Matern R; Baum RP; Seifert R; Kessel K; Bögemann M; Kratochwil C; Rathke H; Ilhan H; Svirydenka H; Sathekge M; Kabasakal L; Yordanova A; Garcia-Perez FO; Kairemo K; Maharaj M; Paez D; Virgolini I; Rahbar K
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4067-4076. PubMed ID: 34031719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
